Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial
Journal of the American Academy of Dermatology Jan 19, 2018
Guttman-Yassky E, et al. - A scrutiny was performed by the authors with regard to the IL-22 blockade in adults with moderate-to-severe atopic dermatitis (AD). The inference drawn was that fezakinumab was well-tolerated. This drug demonstrated sustained clinical improvements after last drug dosing.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
